Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Federal Appeals Court Leaves Blanche's Schedule III Order in Place

11 September 2026 · By · Wire by Fusion42

Published

11 September 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at mgmagazine.com →

◆ Verified

Fusion42 · 11 September 2026 · Fusion42 review

The U.S. Court of Appeals for the D.C. Circuit declined to suspend Attorney General Todd Blanche's order moving certain marijuana products and state-licensed medical marijuana activity to Schedule III of the Controlled Substances Act while legal challenges proceed.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You face a clearer window to operate under Schedule III for certain cannabis products as legal challenges move slowly. Adjust your compliance and market approach to fit the new classification while watching for court rulings that could change the groundwork.

◆ Coverage

1 source · 11 Sep 2026

◆ Related on Wire

◆ Topics

Healthcannabisregulatory-ordercontrolled-substanceslegal-challengeschedule-iii